Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
ESTROSTEP FE SUMMARY
(Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*)
ESTROSTEP® Fe is a graduated estrophasic oral contraceptive providing estrogen in a graduated sequence over a 21-day period with a constant dose of progestogen. ESTROSTEP Fe provides for a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose. Each white triangle-shaped tablet contains 1 mg norethindrone acetate [(17 alpha)-17-(acetyloxy)-19-norpregna-4-en-20-yn-3-one] and 20 mcg ethinyl estradiol [(17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol]; each white square-shaped tablet contains 1 mg norethindrone acetate and 30 mcg ethinyl estradiol; and each white round tablet contains 1 mg norethindrone acetate and 35 mcg ethinyl estradiol. Each tablet also contains calcium stearate; lactose; microcrystalline cellulose; and starch.
ESTROSTEP Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
ESTROSTEP Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. ESTROSTEP Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months.
Media Articles Related to Estrostep Fe (Norethindrone / Estradiol / Norethindrone / Estradiol / Norethindrone / Estradiol)
Domestic violence deters contraception
Source: Abortion News From Medical News Today [2015.04.02]
Domestic violence takes many forms. The control of a woman's reproductive choices by her partner is one of them.
'15 million unwanted pregnancies' created by low contraception in 35 poorer countries
Source: Abortion News From Medical News Today [2015.02.05]
Some 90% of the 16.7 million unwanted pregnancies across a third of the world's population every year are due to a failure to use modern contraception, study suggests.
Research reveals more than half of young women who have abortions were using contraception when they fell pregnant
Source: Abortion News From Medical News Today [2014.04.30]
Reproductive health charity Marie Stopes UK has launched the findings of the first research in the UK into the contraceptive use of women aged 16-24 having one or more abortions.
Adolescent women 'more likely to have unsafe sex' if obese
Source: Sexual Health / STDs News From Medical News Today [2015.07.01]
Obese adolescent women were found less likely to use contraception than their peers with healthy weights, with those that did use contraception less likely to use it consistently.
Female cystic fibrosis patients need more contraceptive guidance, study finds
Source: Cystic Fibrosis News From Medical News Today [2015.05.11]
As life span for once-deadly disease increases, unplanned and mistimed pregnancies are commonOnly half of women with cystic fibrosis (CF) report using contraception and frequently apt to become...
Published Studies Related to Estrostep Fe (Norethindrone / Estradiol / Norethindrone / Estradiol / Norethindrone / Estradiol)
Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. [2007.09]
OBJECTIVE: This study sought to determine whether combined continuous ethinyl estradiol and norethindrone acetate, a postmenopausal hormone therapy (HT) combination designed to have fewer side effects than cyclical therapies and therapies using medroxyprogesterone acetate (MPA), could improve vascular endothelial function in postmenopausal women with risk factors for cardiovascular disease (CVD)... CONCLUSIONS: In this older postmenopausal population with at least one cardiovascular risk factor, treatment with combined continuous ethinyl estradiol and norethindrone acetate failed to improve vascular endothelial function. The agent's proinflammatory effect or subclinical atherosclerosis in this population may have contributed to this finding.
HT update: spotlight on estradiol/norethindrone acetate combination therapy. 
Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman... The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.
A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. 
AIM: This multicenter, open-label, single-arm study evaluated subject satisfaction and improvements in menopausal quality of life among menopausal women using the CombiPatch transdermal system consisting of 17beta-estradiol 0.05 mg plus norethindrone acetate 0.14 mg in a matrix patch formulation... CONCLUSIONS: The results of this study compare favorably with previous placebo-controlled studies of transdermal hormone therapy in managing menopausal signs and symptoms. Furthermore, quality of life was significantly improved by the transdermal hormone therapy system, and both subjects and physicians reported high levels of satisfaction. Copyright 2005 S. Karger AG, Basel
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. [2002.04.15]
OBJECTIVE: To determine the effects of nevirapine (NVP), a nonnucleoside reverse-transcriptase inhibitor of HIV-1 and P450 inducer, on the pharmacokinetics (PK) of ethinyl estradiol (EE)/norethindrone (NET), a widely used oral contraceptive, and to assess the effects of EE/NET on the steady-state PK of NVP... CONCLUSION: Oral contraceptives should not be the primary method of birth control in women of child-bearing potential who are treated with NVP.
Clinical Trials Related to Estrostep Fe (Norethindrone / Estradiol / Norethindrone / Estradiol / Norethindrone / Estradiol)
Gender Disparity and Hormones in Cystic Fibrosis [Recruiting]
The objective of this study is to investigate the impact of hormones on lung disease in
Cystic Fibrosis (CF) patients. Due to improved therapies, CF patients are living longer and
healthier lives than they did 20 years ago. However, females have been shown to have a
survival disadvantage. The median life expectancy is 33 in women and 37 in men with CF. The
hypothesis is that estrogen and/or progesterone negatively impact lung health in CF.
Therefore, understanding the impact of sex hormones (including the use of birth control
pills) on the disease process is increasingly important. The purpose of this study is to
determine if lung function, respiratory symptoms, or various markers of lung health change
during different phases of the natural ovulatory cycle in order to understand if estrogen or
progesterone hormones are impacting the disease relative to fluctuations in men with stable
testosterone levels. The research objectives of this project are to:
- Determine if lung function, respiratory symptoms, or various markers of lung health
change during different hormonal phases of the ovulatory cycle in women.
- Determine if men change lung function, respiratory symptoms, or various markers of lung
health over time.
- Determine if oral contraceptive pills in women stabilize fluctuations in symptoms and
improve lung health.
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation [Recruiting]
The purpose of this research study is to gain a better understanding of the changes that may
occur in the breast when a woman uses an oral contraceptive (birth control pill). Some
research indicates that women who use birth control pills with lower amounts of estrogen (a
hormone in the birth control pill) may have lower breast cell growth than women who use
birth control pills with a higher amount of estrogen; this research will examine that in
detail. This research will also test whether the results found in HS-07-00269 can be
Treatment of Refractory Schizophrenia With Riluzole [Recruiting]
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with
schizophrenia who are already receiving medications, but still experience symptoms.
Neuroprotective medication riluzole is currently approved for treatment of amyotrophic
lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique
mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would
open novel directions in treatment of schizophrenia.
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) [Recruiting]
The purpose of this study is to assess the contraceptive efficacy of a nomegestrol acetate +
17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active
American women at risk for pregnancy. Vaginal bleeding patterns of women taking NOMAC-E2
will be assessed and compared to those of women taking a norethisterone acetate + ethinyl
estradiol (NETA-EE) COC. The safety of NOMAC-E2 will also be assessed.
Participants will be randomized to receive either NOMAC-E2 or NETA-EE in a 3: 1 ratio.
Chronic Pain Risk Associated With Menstrual Period Pain [Recruiting]
The purpose of this study is to determine if some women with dysmenorrhea (painful periods)
are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives
(OC) can be used to reverse this chronic pain risk.
We will examine whether dysmenorrhea produces CPP via repetitive cross organ sensitization
(COS) episodes. The use of cyclical OCs to eliminate dysmenorrhea is expected to reduce COS
and decrease the risk of developing CPP.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Estrostep FE has an overall score of 9. The effectiveness score is 10 and the side effect score is 9. The scores are on ten point scale: 10 - best, 1 - worst.
Estrostep FE review by 29 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || contraceptive|
|Dosage & duration:|| || not sure (dosage frequency: daily) for the period of 8 years|
|Other conditions:|| || no conditions|
|Other drugs taken:|| || none|
|Benefits:|| || this drug claims 99.9% accuracy when administered daily with very little side effects, have been using for several years with no weight gain and no accidents. the packaging is simple, easy and convenient.|
|Side effects:|| || no side effects that i could recognize, pretty common.|
|Comments:|| || dosage is a daily administration, not complex. pretty convenient.|
Estrostep FE review by 27 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || oral contraceptive|
|Dosage & duration:|| || 1 pill a day taken everyday for the period of 4 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || this birth control pills helps your skin if u are someone who breaks out often |
|Side effects:|| || none really but i have increased pms symptoms around 2 weeks beforre my period etc.. certain food cravings, fatigue, muscle weakness. also lost weight from this pill as it suppresses my appetite|
|Comments:|| || one pill a day preferably at the same time every day|
Page last updated: 2015-07-01